Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Almirall

Evaluate

Thumbnail
May 11, 2023

2023’s biggest launches: the story so far

Alzheimer’s has already grabbed attention but plenty of big regulatory decisions still loom for Sarepta, Crispr, Astellas and more.

Thumbnail
June 07, 2022

Lebrikizumab’s convenience edge emerges

Article image
Vantage logo
March 29, 2022

Big pharma’s key second-quarter data

Roche awaits Tigit and Serd data, Lilly takes on obesity, and Glaxo and Pfizer race in RSV.

Article image
Vantage logo
March 28, 2022

AAD 2022 – Lilly gears up to take on Dupixent

Article image
Vantage logo
January 17, 2022

Jaks finally crack atopic dermatitis

Article image
Vantage logo
December 22, 2021

Key big pharma catalysts to kick off 2022

Important breast cancer data will come in the opening months of 2022, and Glaxo and Pfizer are due pivotal RSV results.

Article image
Vantage logo
August 16, 2021

Lilly leaves investors itching for more details

Article image
Vantage logo
August 02, 2021

Lilly’s lebrikizumab looks to outdo Dupixent

Lilly will soon discover whether its purchase of Dermira was wise.

Article image
Vantage logo
June 28, 2021

Key third-quarter readouts for big pharma

Abbvie expects more Rinvoq data in ulcerative colitis while Astrazeneca takes on myasthenia gravis, and gene therapy is in play for Pfizer and Roche.

Article image
Vantage logo
March 24, 2021

Big pharma’s key catalysts in the second quarter

As Biogen heads towards important depression data, Sanofi looks to oncology for growth.

Article image
Vantage logo
February 05, 2021

23andme joins health tech’s Spacmania

But more traditional device makers seem uninterested in this means of stock market listing.

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up